What Atryn and Rhucin have in common
Interesting to see that GTCB's Atryn (rh anti-thrombin) and Pharming's Rhucin (rh c1-inhibitor) have both potentially an important role to play in reducing the negative effects of strokes, ischemia and sepsis. According to several studies both Thrombin and C1 apparently can do a lot of damage during these events and any other traumatic events, where the body defense system (over)reacts. Atryn and Rhucin can mitigate the cascade of overreactions triggered by the body and the damage done by the substances (proteines, peptides, toxicines?) released by the body during those moments.
As an economist I have limited knowledge of things like pathways and contact systems, that's why I put it in layman's words. But to me it seems there are huge applications for Atryn and Rhucin. If the two companies (GTCB and Pharming)could combine, they might even have substantial synergies if they were to concentrate on these common application areas (i.e. ischemia, sepsis etc). Synergies could be obtained by streamlining research collaborations, the focus of their own staff and, who knows, the recruitment of patients for clinical trials within the same clinical centers. This apart from the obvious synergies there are by bringing all transgenics IP under one roof.
Any ideas from the specialists on this?
News 
Market Data 
Discover 
AI
